Literature DB >> 7521899

Locations of antibody binding sites within conserved regions of the hepatitis C virus core protein.

M Sällberg1, P Pumpen, Z X Zhang, P Lundholm, I Gusars, U Rudén, B Wahren, L O Magnius.   

Abstract

The binding sites for human antibodies recognising antigenic domains within the hepatitis C virus (HCV) core protein were analyzed using synthetic peptides. Omission peptide analogues where a pair of residues was sequentially omitted were produced corresponding to the regions 1-18, 11-28, 21-38, 51-68, and 101-118. The N-terminal part of HCV core was found to contain three distinct antibody binding sites, which includes the previously reported one at residues 9-16. The other two were located at residues 19-26 and residues 29-34. Within the region 51-68 two overlapping sites were found, the first at residues 51-60 and the second at residues 59-68. Within the region 101-118, residues 107-114 were identified as the binding site, which contains two residues differing between genotypes I/II and III/VI. Thus the HCV core protein contains at least six distinct linear antibody binding sites, located at regions highly conserved between the genotypes of HCV. The human recognition of these regions show a variation with respect to the amino- and carboxy-terminal extension of each individual binding site. These findings will have implications for the prediction of the structure of the HCV core protein, since these antibody binding sequences are likely to be more or less accessible from the exterior of either, or both, of the native HCV core and its precursor polyprotein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521899     DOI: 10.1002/jmv.1890430112

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Characterization of a panel of monoclonal antibodies and mapping the epitopes of hepatitis C virus proteins.

Authors:  O V Masalova; A G Abdulmedzhidova; S N Atanadze; E I Lakina; YuA Semiletov; A N Burkov; T I Ulanova; V V Novikov; V K Pimenov; G Filds; YuE Khudyakov; A A Kushch
Journal:  Dokl Biochem Biophys       Date:  2002 Mar-Apr       Impact factor: 0.788

Review 2.  The humoral immune response in acute and chronic hepatitis B virus infection.

Authors:  D R Milich; M Sallberg; T Maruyama
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Improved reactivity of hepatitis C virus core protein epitopes in a conformational antigen-presenting system.

Authors:  E Buratti; M Di Michele; P Song; C Monti-Bragadin; E A Scodeller; F E Baralle; S G Tisminetzky
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

4.  Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes.

Authors:  Irina Sominskaya; Dace Skrastina; Andris Dislers; Denis Vasiljev; Marija Mihailova; Velta Ose; Dzidra Dreilina; Paul Pumpens
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

5.  Levels of hepatitis C virus (HCV) RNA in serum and their relationship to levels of immunoglobulin M and G antibodies against HCV core protein.

Authors:  M Chen; A Sönnerborg; M Sällberg
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

6.  Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.

Authors:  Shingo Nakamoto; Fumio Imazeki; Makoto Arai; Shin Yasui; Masato Nakamura; Yuki Haga; Reina Sasaki; Tatsuo Kanda; Hiroshi Shirasawa; Osamu Yokosuka
Journal:  Int J Mol Sci       Date:  2015-09-07       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.